Combination antiviral therapy for influenza: Predictions from modeling of human infections

Journal of Infectious Diseases

Volumn 205, Issue 11, 2012, Pages 1642-1645

  Perelson, Alan S ^a   Rong, Libin ^a,b   Hayden, Frederick G ^c,d  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b OAKLAND UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANIMAL CELL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CRITICALLY ILL PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; NONHUMAN; PANDEMIC INFLUENZA; PREDICTION; PRIORITY JOURNAL; RISK REDUCTION; SEASONAL INFLUENZA; STATISTICAL MODEL; VIRUS MUTANT; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; CHEMOPREVENTION; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HUMANS; INFLUENZA, HUMAN; MODELS, THEORETICAL; MUTATION; ORTHOMYXOVIRIDAE; SELECTION, GENETIC;

EID: 84861039644     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis265     Document Type: Article

References (16)

1. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 203:6-10.
2. Sheu TG, Fry AM, Garten RJ, et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. J Infect Dis 2011; 203:13-7.
3. Murphy BR, Rennels MB, Douglas RG Jr, et al. Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun 1980; 29:348-55. (Pubitemid 10040141)
4. Lee N, Chan PK, Wong CK, et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011; 16:237-47.
5. Beauchemin CA, McSharry JJ, Drusano GL, et al. Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol 2008; 254:439-51.
6. Handel A, Longini IM Jr, Antia R. Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput Biol 2007; 3:e240.
7. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-7. (Pubitemid 44527358)
8. Menache MG, Hanna LM, Gross EA, et al. Upper respiratory tract surface areas and volumes of laboratory animals and humans: considerations for dosimetry models. J Toxicol Environ Health 1997; 50:475-506.
9. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza Avirus infection in humans. J Virol 2006; 80:7590-9. (Pubitemid 44092580)
10. Hoopes JD, Driebe EM, Kelley E, et al. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One 2011; 6:e29778.
11. Saenz RA, Quinlivan M, Elton D, et al. Dynamics of influenza virus infection and pathology. J Virol 2010; 84:3974-83.
12. Mohler L, Flockerzi D, Sann H, Reichl U. Mathematical model of influenza A virus production in large-scale microcarrier culture. Biotechnol Bioeng 2005; 90:46-58. (Pubitemid 40547038)
13. Nobusawa E, Sato K. Comparison of the mutation rates of human influenza A and B viruses. J Virol 2006; 80:3675-8.
14. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol 1986; 59:377-83. (Pubitemid 16013985)
15. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328:1272-5.
16. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 5: e9332.